BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 276 filers reported holding BIO-TECHNE CORP in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,299,223 | +83344.0% | 19,087 | +0.1% | 0.29% | -15.3% |
| Q2 2023 | $1,557 | +5.3% | 19,071 | -4.9% | 0.34% | +8.6% |
| Q1 2023 | $1,479 | -11.2% | 20,050 | -0.3% | 0.31% | -16.8% |
| Q4 2022 | $1,666 | -99.9% | 20,102 | +292.9% | 0.38% | +6.8% |
| Q3 2022 | $1,519,000 | -24.2% | 5,116 | -11.3% | 0.35% | -22.0% |
| Q2 2022 | $2,004,000 | -22.2% | 5,771 | -3.0% | 0.45% | -8.7% |
| Q1 2022 | $2,577,000 | -30.8% | 5,951 | -24.9% | 0.49% | -30.9% |
| Q4 2021 | $3,726,000 | -5.6% | 7,925 | -2.7% | 0.72% | -3.5% |
| Q3 2021 | $3,948,000 | +3.9% | 8,148 | -1.7% | 0.74% | -9.2% |
| Q2 2021 | $3,799,000 | +16.5% | 8,290 | -1.4% | 0.82% | +15.1% |
| Q1 2021 | $3,260,000 | +19.9% | 8,409 | -2.7% | 0.71% | +12.5% |
| Q4 2020 | $2,720,000 | +26.7% | 8,642 | -0.6% | 0.63% | +0.6% |
| Q3 2020 | $2,147,000 | -12.0% | 8,693 | -2.4% | 0.63% | -13.1% |
| Q2 2020 | $2,440,000 | +39.8% | 8,911 | -3.2% | 0.72% | +4.8% |
| Q1 2020 | $1,745,000 | -19.4% | 9,207 | -5.8% | 0.69% | +0.7% |
| Q4 2019 | $2,164,000 | +8.0% | 9,772 | +2.5% | 0.68% | -1.0% |
| Q2 2019 | $2,003,000 | +93.9% | 9,532 | +11.5% | 0.69% | +58.0% |
| Q3 2017 | $1,033,000 | +3.9% | 8,549 | +1.0% | 0.44% | -11.0% |
| Q2 2017 | $994,000 | +9.0% | 8,462 | +2.3% | 0.49% | +23.1% |
| Q1 2017 | $912,000 | +18.1% | 8,274 | +10.2% | 0.40% | +2.1% |
| Q4 2016 | $772,000 | -6.5% | 7,511 | -0.4% | 0.39% | -5.1% |
| Q3 2016 | $826,000 | +4.0% | 7,543 | +5.9% | 0.41% | -7.0% |
| Q2 2016 | $794,000 | – | 7,123 | – | 0.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |